Hims & Hers' Investments Seen Offering Long-Term Advantages -- Market Talk

Dow Jones05-13

1339 ET - Hims & Hers Health is in the midst of another big spending year that's putting pressure on its margins, but the investments should become long-term differentiators for the telehealth company, BofA Securities analysts say in a note. The analysts say they are particularly optimistic about the investments Hims & Hers is making in verticalizing its supply chain and scaling internationally. "HIMS' investments in these areas position the company to exploit the peptide opportunity (to the extent they are able to) and become a global platform of choice for large pharma," the analysts say. However, in the near-term, Wall Street's estimates look too high, the analysts say, backing their neutral rating on the stock and lowering their price target to $30 from $32, pointing in part to execution risks related to the investments. Hims & Hers Health slides nearly 14%.(kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

May 12, 2026 13:39 ET (17:39 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635843241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 01:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635843241","market":"hk","top_or_hot":-1,"title":"Hims & Hers' Investments Seen Offering Long-Term Advantages -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1339 ET - Hims &amp; Hers Health is in the midst of another big spending year that's putting pressure on its margins, but the investments should become long-term differentiators for the telehealth company, BofA Securities analysts say in a note. The analysts say they are particularly optimistic about the investments Hims &amp; Hers is making in verticalizing its supply chain and scaling internationally. \"HIMS' investments in these areas position the company to exploit the peptide opportunity (to the extent they are able to) and become a global platform of choice for large pharma,\" the analysts say. However, in the near-term, Wall Street's estimates look too high, the analysts say, backing their neutral rating on the stock and lowering their price target to $30 from $32, pointing in part to execution risks related to the investments. Hims &amp; Hers Health slides nearly 14%.(kelly.cloonan@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 13:39 ET (17:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers' Investments Seen Offering Long-Term Advantages -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers' Investments Seen Offering Long-Term Advantages -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-13 01:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1339 ET - Hims &amp; Hers Health is in the midst of another big spending year that's putting pressure on its margins, but the investments should become long-term differentiators for the telehealth company, BofA Securities analysts say in a note. The analysts say they are particularly optimistic about the investments Hims &amp; Hers is making in verticalizing its supply chain and scaling internationally. \"HIMS' investments in these areas position the company to exploit the peptide opportunity (to the extent they are able to) and become a global platform of choice for large pharma,\" the analysts say. However, in the near-term, Wall Street's estimates look too high, the analysts say, backing their neutral rating on the stock and lowering their price target to $30 from $32, pointing in part to execution risks related to the investments. Hims &amp; Hers Health slides nearly 14%.(kelly.cloonan@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 12, 2026 13:39 ET (17:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635843241","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635843241","pubTimestamp":1778607540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1339 ET - Hims & Hers Health is in the midst of another big spending year that's putting pressure on its margins, but the investments should become long-term differentiators for the telehealth company, BofA Securities analysts say in a note. The analysts say they are particularly optimistic about the investments Hims & Hers is making in verticalizing its supply chain and scaling internationally. \"HIMS' investments in these areas position the company to exploit the peptide opportunity  and become a global platform of choice for large pharma,\" the analysts say. However, in the near-term, Wall Street's estimates look too high, the analysts say, backing their neutral rating on the stock and lowering their price target to $30 from $32, pointing in part to execution risks related to the investments. Hims & Hers Health slides nearly 14%.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","HIMY":"Defiance Leveraged Long + Income HIMS ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","HIYY":"YieldMax HIMS Option Income Strategy ETF","HMYY":"GraniteShares YieldBoost HIMS ETF","HIMS":"Hims & Hers Health Inc."},"translate_title":"Hims&Hers的投资被认为具有长期优势——市场讨论","themeId":"89a4eb0c97016e8640c4422499c1632e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIYY":0.6,"HMYY":0.6,"HIMS":1.96,"HIMY":0.6,"HIMZ":0.6},"content_text":"1339 ET - Hims & Hers Health is in the midst of another big spending year that's putting pressure on its margins, but the investments should become long-term differentiators for the telehealth company, BofA Securities analysts say in a note. The analysts say they are particularly optimistic about the investments Hims & Hers is making in verticalizing its supply chain and scaling internationally. \"HIMS' investments in these areas position the company to exploit the peptide opportunity (to the extent they are able to) and become a global platform of choice for large pharma,\" the analysts say. However, in the near-term, Wall Street's estimates look too high, the analysts say, backing their neutral rating on the stock and lowering their price target to $30 from $32, pointing in part to execution risks related to the investments. Hims & Hers Health slides nearly 14%.(kelly.cloonan@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 13:39 ET (17:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635843241","isCrawlerRequest":true}